Stay updated with breaking news from Mark Lanasa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting ... | April 20, 2023
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment settingBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its pr...
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene
10.09.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid ... Seite 1